breast cancer

[Genentech] Genentech announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® in combination with chemotherapy for the treatment of adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1, as determined by a US FDA-approved test.

[Scientific Reports] Hormone receptor positive, reduction mammoplasty-derived human breast epithelial progenitors were exposed to a short-term, pregnancy-level of estradiol, and their subsequent response to estradiol stimulation was analyzed.

[Molecular Therapy] The authors identified a circRNA termed circ-EIF6, which predicted a poorer prognosis and correlated with clinicopathological characteristics in a cohort of TNBC patients. Functionally, they showed that circ-EIF6 promoted the proliferation and metastasis of TNBC cells in vitro and in vivo.

[Nature Communications] The authors showed that triple inhibition with fulvestrant, CDK4/6i and AKT inhibitor durably impaired growth of breast cancer cells, prevented progression and reduced metastasis of tumor xenografts resistant to CDK4/6i-fulvestrant combination or fulvestrant alone.

[Nanomedicine] Investigators evaluated the anti breast-cancer activity, biocompatibility, and toxicity of poly(d,l)-lactic-co-glycolic acid-encapsulated quercetin nanoparticles. Activity against CAL51 and MCF7 cell lines was assessed by DNA fragmentation assays, fluorescence microscopy, and acridine-orange, and propidium-iodide double-stainings.

[Journal of the American Chemical Society] Seven CADA compounds (CADA, VGD020, VGD071, TL020, TL023, LAL014, and DJ010) were examined for reduction of cellular sortilin expression and progranulin-induced breast cancer stem cell propagation.